Invivo anti-mouse CD96 Recombinant mAb

CD96, also known as TACTILE (T cell activation, increased late expression), is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily, encoded by the CD96 gene. It is primarily expressed on T cells and natural killer (NK) cells, and is involved in immune regulation. CD96 shares sequence similarity with CD226 (DNAM-1) and competes with it for binding to CD155, its main ligand. This interaction can inhibit NK cell function and cytokine responses, making CD96 a potential target for cancer immunotherapy. Research has shown that blocking CD96 can enhance antitumor immunity, particularly when combined with other treatments such as anti-PD-1 or anti-CTLA-4 therapies. Additionally, CD96 expression is associated with immune infiltration and poor clinical outcomes in some cancers, further highlighting its potential as a therapeutic target.